CXXI Stock Overview
An integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
C21 Investments Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.40 |
| 52 Week High | CA$0.64 |
| 52 Week Low | CA$0.27 |
| Beta | 2.42 |
| 1 Month Change | -27.27% |
| 3 Month Change | -20.00% |
| 1 Year Change | -1.23% |
| 3 Year Change | -69.92% |
| 5 Year Change | -60.78% |
| Change since IPO | -98.40% |
Recent News & Updates
C21 Investments Inc.'s (CSE:CXXI) 30% Share Price Surge Not Quite Adding Up
May 12
A Look At The Intrinsic Value Of C21 Investments Inc. (CSE:CXXI)
May 01Recent updates
C21 Investments Inc.'s (CSE:CXXI) 30% Share Price Surge Not Quite Adding Up
May 12A Look At The Intrinsic Value Of C21 Investments Inc. (CSE:CXXI)
May 01Some Confidence Is Lacking In C21 Investments Inc. (CSE:CXXI) As Shares Slide 27%
Mar 09Is C21 Investments (CSE:CXXI) A Risky Investment?
Sep 04These 4 Measures Indicate That C21 Investments (CSE:CXXI) Is Using Debt Reasonably Well
Mar 21These 4 Measures Indicate That C21 Investments (CSE:CXXI) Is Using Debt Reasonably Well
Nov 29C21 Investments Inc. (CSE:CXXI) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Oct 12A Look At The Fair Value Of C21 Investments Inc. (CSE:CXXI)
Apr 22Does C21 Investments (CSE:CXXI) Have A Healthy Balance Sheet?
Mar 22C21 Investments' (CSE:CXXI) Solid Earnings May Rest On Weak Foundations
Oct 05We Think C21 Investments (CSE:CXXI) Can Stay On Top Of Its Debt
Sep 03C21 Investments (CSE:CXXI) Seems To Use Debt Quite Sensibly
Mar 07Shareholder Returns
| CXXI | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -13.0% | -0.8% | -0.5% |
| 1Y | -1.2% | 46.7% | 11.9% |
Return vs Industry: CXXI underperformed the Canadian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: CXXI underperformed the Canadian Market which returned 11.9% over the past year.
Price Volatility
| CXXI volatility | |
|---|---|
| CXXI Average Weekly Movement | 18.7% |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: CXXI's share price has been volatile over the past 3 months.
Volatility Over Time: CXXI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Sonny Newman | www.cxxi.ca |
C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. The company offers packaged and wholesale vaporizer pens, flowers, cured resin extracts, edibles, pre-rolls, tinctures, and topicals. It also provides payroll and benefits services.
C21 Investments Inc. Fundamentals Summary
| CXXI fundamental statistics | |
|---|---|
| Market cap | CA$48.02m |
| Earnings (TTM) | -CA$3.37m |
| Revenue (TTM) | CA$38.54m |
1.2x
P/S Ratio-14.3x
P/E RatioIs CXXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CXXI income statement (TTM) | |
|---|---|
| Revenue | US$28.29m |
| Cost of Revenue | US$17.14m |
| Gross Profit | US$11.15m |
| Other Expenses | US$13.62m |
| Earnings | -US$2.47m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 39.42% |
| Net Profit Margin | -8.74% |
| Debt/Equity Ratio | 7.4% |
How did CXXI perform over the long term?
See historical performance and comparison